This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Novo Nordisk A/S
Drug Names(s): Degludec, Soluble insulin basal analogue (SIBA), NN1250, IDeg
Description: Degludec (NN1250) is a neutral, soluble, long-acting insulin analogue with a flat and predictable profile providing more than 24-hour coverage by once-daily injection.
Degludec will be provided in a new and improved disposable pen, called the PDS290 pen.
Additional information available to subscribers only: